Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care

By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, LLC ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the first patient has been dosed in its Phase 2 clinical trial of MAR002 for the treatment of acromegaly.

Acromegaly is a rare, chronic, progressive endocrine disorder caused by prolonged exposure to excess growth hormone (GH), most commonly due to a GH-secreting pituitary adenoma, resulting in elevated insulin-like growth factor-1 (IGF-1). It leads to the abnormal enlargement of the hands, feet, and facial features, and if left untreated, can result in severe organ damage, systemic complications, and early mortality.

MAR002 is a first-in-class allosteric monoclonal antibody investigational therapy targeting the growth hormone receptor (GHR). Data from a first-in-human Phase 1 study with MAR002 presented at the 2026 Annual Meeting of the Endocrine Society (ENDO) in June 2026 demonstrated compelling proof-of-mechanism with deep and durable IGF-1 suppression and pharmacokinetic (PK) properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care.